THERAPY DOSSIER · th-c7989ef6f84c

Brain-derived neurotrophic factor-transfected mesenchymal stem cell spheroids (non-viral transfection with biodegradable polycations, three-dimensional spheroid culture)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27639527 ↗2016Reported benefit

Treatment of spinal cord injury by an advanced cell transplantation technology using brain-derived neurotrophic factor-transfected mesenchymal stem cell spheroids.

MouseSpinal cord injuryUnspecifiedC57BL/6 (Mice, Inbred C57BL)FemaleTransplantation into the spinal cord injury region at Th9Acute phase of spinal cord injury (exact interval not stated)

Model: Spinal cord injury at thoracic level Th9

Transplantation of brain-derived neurotrophic factor-transfected mesenchymal stem cell spheroids significantly enhanced hindlimb motor recovery in the acute phase and preserved myelinated axons at the injury site, whereas either transfection or spheroid culture alone gave only a limited therapeutic…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…